Ideaya Biosciences Stock Not Fully Reflecting Phase 2/3 Data From Metastatic Uveal Melanoma Study, RBC Says

MT Newswires Live

04/14

Ideaya Biosciences (IDYA) stock is not fully reflecting the strength of the data from the company's phase 2/3 trial evaluating darovasertib combined with crizotinib for metastatic uveal melanoma, RBC Capital Markets said in a note Monday.

Analysts said they are "positive" on the meaningfulness of the data, the regulatory strategy for the new drug application in H2 of this year, and Ideaya's commercial positioning ahead of a 2027 launch.

RBC said that the key opinion leaders invited to a call with the company were excited about the drug's ability to offer patients a high response rate and significant progression-free survival.

Analysts said that the next key catalysts for the program include overall survival data and neo-adjuvant readouts, potentially in 2027.The ultimate overall survival readout is also likely to come in positive, they said.

RBC has an outperform rating on the stock. It increased the price target to $53 from $49.

Price: 31.24, Change: -1.58, Percent Change: -4.81

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2627744037"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2627744037\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2627744037?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 23:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627744037","market":"nz","top_or_hot":-1,"title":"Ideaya Biosciences Stock Not Fully Reflecting Phase 2/3 Data From Metastatic Uveal Melanoma Study, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Ideaya Biosciences (IDYA) stock is not fully reflecting the strength of the data from the company's phase 2/3 trial evaluating darovasertib combined with crizotinib for metastatic uveal melanoma, RBC Capital Markets said in a note Monday.</p><p>Analysts said they are \"positive\" on the meaningfulness of the data, the regulatory strategy for the new drug application in H2 of this year, and Ideaya's commercial positioning ahead of a 2027 launch.</p><p>RBC said that the key opinion leaders invited to a call with the company were excited about the drug's ability to offer patients a high response rate and significant progression-free survival.</p><p>Analysts said that the next key catalysts for the program include overall survival data and neo-adjuvant readouts, potentially in 2027.The ultimate overall survival readout is also likely to come in positive, they said.</p><p>RBC has an outperform rating on the stock. It increased the price target to $53 from $49.</p><p>Price: 31.24, Change: -1.58, Percent Change: -4.81</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ideaya Biosciences Stock Not Fully Reflecting Phase 2/3 Data From Metastatic Uveal Melanoma Study, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIdeaya Biosciences Stock Not Fully Reflecting Phase 2/3 Data From Metastatic Uveal Melanoma Study, RBC Says\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-04-14 23:13</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Ideaya Biosciences (IDYA) stock is not fully reflecting the strength of the data from the company's phase 2/3 trial evaluating darovasertib combined with crizotinib for metastatic uveal melanoma, RBC Capital Markets said in a note Monday.</p><p>Analysts said they are \"positive\" on the meaningfulness of the data, the regulatory strategy for the new drug application in H2 of this year, and Ideaya's commercial positioning ahead of a 2027 launch.</p><p>RBC said that the key opinion leaders invited to a call with the company were excited about the drug's ability to offer patients a high response rate and significant progression-free survival.</p><p>Analysts said that the next key catalysts for the program include overall survival data and neo-adjuvant readouts, potentially in 2027.The ultimate overall survival readout is also likely to come in positive, they said.</p><p>RBC has an outperform rating on the stock. It increased the price target to $53 from $49.</p><p>Price: 31.24, Change: -1.58, Percent Change: -4.81</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2627744037","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627744037","pubTimestamp":1776179607,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ideaya Biosciences  stock is not fully reflecting the strength of the data from the company's phase 2/3 trial evaluating darovasertib combined with crizotinib for metastatic uveal melanoma, RBC Capital Markets said in a note Monday.Analysts said they are \"positive\" on the meaningfulness of the data, the regulatory strategy for the new drug application in H2 of this year, and Ideaya's commercial positioning ahead of a 2027 launch.RBC said that the key opinion leaders invited to a call with the company were excited about the drug's ability to offer patients a high response rate and significant progression-free survival.Analysts said that the next key catalysts for the program include overall survival data and neo-adjuvant readouts, potentially in 2027.The ultimate overall survival readout is also likely to come in positive, they said.RBC has an outperform rating on the stock. It increased the price target to $53 from $49.Price: 31.24, Change: -1.58, Percent Change: -4.81","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IDYA":"IDEAYA Biosciences"},"translate_title":"RBC表示，Ideaya Biosciences股票并未完全反映转移性葡萄膜黑色素瘤研究的2/3期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDYA":1},"content_text":"Ideaya Biosciences (IDYA) stock is not fully reflecting the strength of the data from the company's phase 2/3 trial evaluating darovasertib combined with crizotinib for metastatic uveal melanoma, RBC Capital Markets said in a note Monday.Analysts said they are \"positive\" on the meaningfulness of the data, the regulatory strategy for the new drug application in H2 of this year, and Ideaya's commercial positioning ahead of a 2027 launch.RBC said that the key opinion leaders invited to a call with the company were excited about the drug's ability to offer patients a high response rate and significant progression-free survival.Analysts said that the next key catalysts for the program include overall survival data and neo-adjuvant readouts, potentially in 2027.The ultimate overall survival readout is also likely to come in positive, they said.RBC has an outperform rating on the stock. It increased the price target to $53 from $49.Price: 31.24, Change: -1.58, Percent Change: -4.81","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}